REG - IXICO plc - Holding(s) in Company

IXICOAnnouncement

Thu 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250508:nRSH9099Ha&default-theme=true

RNS Number : 9099H  IXICO plc  08 May 2025

8 May 2025

 

IXICO plc

 

("IXICO", the "Company" or the "Group")

 

Holding(s) in Company

 

IXICO plc (the "Company"), announces that it was notified by Amati Global
Investors Limited on 6 May 2025 that, as of 1 May 2025, the Investment Manager
of Amati AIM VCT plc changed from Amati Global Investors Limited to Maven
Capital Partners UK LLP, following which the name of the shareholder changed
from Amati AIM VCT plc to Maven Renovar VCT plc. There has been no change to
the position held in the Company.

Further information concerning the notification of major holdings is provided
below.

Ends

 

Further information:

 

 IXICO plc                                                                         +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and                          +44 (0) 20 7220 0500

 Sole Broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BFXR4C20

Issuer Name

IXICO PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

Other

Comments

Please refer to the Additional Information section below. There has been no
change to the position held in the Issuer.

3. Details of person subject to the notification obligation

Name

Amati Global Investors Limited

City of registered office (if applicable)

Edinburgh

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

 Name                   City of registered office  Country of registered office
 Maven Renovar VCT plc  London                     United Kingdom

5. Date on which the threshold was crossed or reached

01-May-2025

6. Date on which Issuer notified

06-May-2025

7. Total positions of person(s) subject to the notification obligation

                                                                            % of voting rights attached to shares (total of 8.A)  % of voting rights through financial instruments (total of 8.B 1 + 8.B 2)  Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer
 Resulting situation on the date on which threshold was crossed or reached  0.000000                                              0.000000                                                                   0.000000                        0
 Position of previous notification (if applicable)                          9.830000                                              0.000000                                                                   9.830000

8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached

8A. Voting rights attached to shares

 Class/Type of shares ISIN code(if possible)  Number of direct voting rights (DTR5.1)  Number of indirect voting rights (DTR5.2.1)  % of direct voting rights (DTR5.1)  % of indirect voting rights (DTR5.2.1)
 GB00BFXR4C20                                 0                                        0                                            0.000000                            0.000000
 Sub Total 8.A                                0                                                                                     0.000000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

 Type of financial instrument  Expiration date  Exercise/conversion period  Number of voting rights that may be acquired if the instrument is  % of voting rights
                                                                            exercised/converted

 Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))

 Type of financial instrument  Expiration date  Exercise/conversion period  Physical or cash settlement  Number of voting rights  % of voting rights

 Sub Total 8.B2

9. Information in relation to the person subject to the notification
obligation

1. Person subject to the notification obligation is not controlled by any
natural person or legal entity and does not control any other undertaking(s)
holding directly or indirectly an interest in the (underlying) issuer.

 Ultimate controlling person  Name of controlled undertaking  % of voting rights if it equals or is higher than the notifiable threshold  % of voting rights through financial instruments if it equals or is higher  Total of both if it equals or is higher than the notifiable threshold
                                                                                                                                          than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

On 1st May 2025 the Investment Manager of Amati AIM VCT plc (the "Company")
changed from Amati Global Investors Limited to Maven Capital Partners UK LLP,
following which the name of the Company changed from Amati AIM VCT plc to
Maven Renovar VCT plc. There has been no change to the position held in the
Issuer.

12. Date of Completion

06-May-2025

13. Place Of Completion

Edinburgh, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLAPMMTMTTMBRA